Evaluation of gemifloxacin (SB-265805, LB20304a): In vitro activity against over 6000 Gram-positive pathogens from diverse geographic areas

International Journal of Antimicrobial Agents

Volumn 15, Issue 3, 2000, Pages 227-230

  Jones, Ronald N ^a   Pfaller, Michael A ^a   Erwin, Meredith E ^a  

^a Anti Infectives Surveillance and Testing   (United States)

Author keywords

Gemifloxacin; Gram positive organisms; Resistance

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GEMIFLOXACIN; OXACILLIN; PENICILLIN G; TROVAFLOXACIN; VANCOMYCIN;

ANALYTIC METHOD; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; ENTEROCOCCUS FAECALIS; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; EUROPE; FLUOROQUINOLONES; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; NORTH AMERICA; SOUTH AMERICA;

EID: 0033846399     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00173-4     Document Type: Article

References (9)

1. Oh J.I., Paek K.S., Ahn M.J., Kim M.Y., Hong C.Y., Kim I.C. et al. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. Antimicrob. Agents Chemother. 40:1996;1564-1568.
2. Cormican M.G., Jones R.N. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrob. Agents Chemother. 41:1997;204-211.
3. Hohl A.F., Frei R., Punter V. et al. International multi-center investigation of LB20304, a new fluoronaphthyridone. Clin. Microbiol. Infect. 4:1998;280-283.
4. Bauernfeind A. Comparison of the antibacterial activities of the quinolones BAY 12-8039, gatifloxacin (AM-1155), trovafloxacin, clinafloxacin, levofloxacin, and ciprofloxacin. J. Antimicrob. Chemother. 40:1997;639-651.
5. Marco F., Barrett M.S., Jones R.N. Antimicrobial activity of LB20304, a fluoronaphthyridone tested against anaerobic bacteria. J. Antimicrob. Chemother. 40:1997;605-607.
6. Domagala J.M. Structure-activity and structure-side effect relationship for the quinolone antibacterials. J. Antimicrob. Chemother. 33:1994;685-706.
7. Kim S.Y., Kim H.J., Kwak J.H., Kim I.C., Lee C.H. Safety evaluation of LB20304, a new quinolone antibiotic. J. Appl. Pharmacol. 3:1995;322-326.
8. National Committee for Clinical Laboratory Standards (NCCLS) 1997. Standard methods for antimicrobial susceptibility tests for bacteria that grow aerobically: Approved standard M7-A4, Wayne, PA:NCCLS.
9. National Committee for Clinical Laboratory Standards (NCCLS) 1999. Performance standards for antimicrobial susceptibility testing; Ninth informational supplement M100-S9, National Committee for Clinical Laboratory Standards, Wayne, PA